Teclistamab impairs vaccine response to S. pneumoniae. (A) Response after vaccination against S. pneumoniae in patients treated with teclistamab (n = 17). Control groups were patients with NDMM on maintenance therapy after autologous stem cell transplantation (n = 22), patients with daratumumab-naive RRMM (n = 11), and patients with RRMM treated with a daratumumab-containing regimen (n = 20). Response rates were compared using Pearson χ2 test or Fisher exact test. (B) Peak specific IgG titers (μg/mL) against pneumococcal serotypes 6B, 8, 9V, 14, 15B, 19F, 20, 23F, and 33F, assessed by enzyme-linked immunosorbent assay, after PCV-13 and PPV-23 vaccination in the teclistamab-treated and control groups. Data are depicted as violin plots, indicating the distribution, including the median and interquartile range. Groups were compared using Kruskal-Wallis test with Dunns correction for multiple comparisons. RRMM-DARA naive, patients with daratumumab-naive RRMM; RRMM-DARA, patients with RRMM treated with a daratumumab-containing regimen; RRMM-TEC, patients with RRMM treated with teclistamab; ns, not significant. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; and ∗∗∗∗P < .0001.
